Risk of systemic toxicity from topical ophthalmic chloramphenicol

Scottish Medical Journal

Volumn 53, Issue 3, 2008, Pages 54-55

  Phillips, C I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAMPHENICOL; EYE DROPS; EYE OINTMENT; PROPAMIDINE ISETHIONATE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BLOOD DYSCRASIA; CONJUNCTIVITIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG FATALITY; DRUG LEGISLATION; FIRST PASS EFFECT; HUMAN; LETTER; NETHERLANDS; PRESCRIPTION; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; ARTICLE; CHEMICALLY INDUCED DISORDER; HEMATOLOGIC DISEASE;

ANTI-BACTERIAL AGENTS; CHLORAMPHENICOL; HEMATOLOGIC DISEASES; HUMANS; OPHTHALMIC SOLUTIONS;

EID: 54049106546     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1258/RSMSMJ.53.3.54     Document Type: Letter

References (36)

1. Everitt HA, Little PS, Smith PWF. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ 2006; 333: 321-324.
2. Rose PW, Hamden A, Brueggemann AB et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care. Lancet 2005; 366: 37-43.
3. Robbie SJ, Qureshi K, Kashani S et al. Research into management strategies for acute infective conjunctivitis. Brit Med J 2006; 333: 446-447.
4. Kumar P, Clark M (eds). Clinical Medicine. 5th ed. London: Bailliere Tindall, WB Saunders, 2002. p40.
5. McKusick VA. Mendelian Inheritance in Man vol 3. 12th ed. Baltimore and London: The John Hopkins University Press, 1998. 3576 (no.515000)
6. Fernandez de Sevilla T, Alegre J, Vallespi T et al. Adult pure red cell aplasia following topical ocular chloramphenicol. Br J Ophthalmol 1990; 74: 640.
7. Shell JW. Pharmocokinetics of topically applied drugs. Surv Ophthalmol 1982; 26: 207-218.
8. McCurdy C. Plasma concentration of chloramphenicol and bone marrow suppression. Blood 1963; 21: 363-372.
9. Kapusnik-Uner JE, Saude MA, Chambers HF. Anti-microbial agents, tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In Hardman JG, Limbird LE et al (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York McGraw Hill, 1996. p 1132
10. West JB (ed). Best and Taylor's Physiological Basis of Medical Practice. Baltimore: Williams and Wilkins, 1990. p119
11. Shearman DJC, Finlayson N, Camilleri M, et al (eds) Diseases of the Gastrointestinal Tract and Liver 3rd ed. New York: Churchill Livingstone, 1970. p715.
12. Rhoades RA, Tanner GA (eds) Medical Physiology. New York, Boston: Little Brown and Co, 1995. p426
13. Chambers HF. Choramphenicol, tetracyclines, macrolides, clindamycin, & streptogramins. In Katzung BG (ed) Basic and Clinical Pharmacology. 8th ed. New York: Lange Medical Books/McGraw Hill, 2001. p775
14. Normann Ek, Bakken O, Peltola J, et al. Treatment of acute neonatal bacterial conjunctivitis: a comparison of fucidic acid to chloramphenicol eye drops. Acta Ophthalmol Scand 2002; 80: 183-187.
15. Pamphlet accompanying package of drops "Optrex". Infected eyes: eye drops: choloramphenicol. 2007.
16. Rosenthal RL, Blackman A. Bone marrow hypoplasia following the use of chloramphenicol eye drops. JAMA 1965; 191: 136-137.
17. Frauenfelder FT, Bagby GC Jr, et al. Fatal aplastic anaemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93: 356
18. Frauenfelder FT, Morgan RL, Yunis AA. Blood dyscrasia and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993; 115: 812-3.
19. Adler G, McElwain GE, Merli GJ et al. Systemic effects of eyedrops. Arch Intern Med 1982; 142: 2293-4.
20. Davidson SI. Systemic effects of eyedrops. Trans Ophthalmol Soc UK 1974; 94: 487-494.
21. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? Authors' reply. BMJ 1995; 311: 451.
22. Lancaster T, Swart AM, Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. BMJ 1998; 316: 667.
23. Smith AG, Dovey GJ, Cartwright RA. Topical chloramphenicol and the risk of acute leukaemia in adults. Pharmacoepidemiol Drug Saf 2000; 9: 215-219.
24. Hall AV, Das SS, Tabaqchali S. Is it time to stop using chloramphenicol on the eye? Risk is low in short courses. BMJ 1995; 311: 450.
25. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? BMJ 1995; 310: 1217-8.
26. Buckley RJK, Kirkness CM, Kanski JJ et al. Is it time to stop using chloramphenicol on the eye? Safe in patients with no history of blood dyscrasia. BMJ 1995; 311: 450.
27. Mulla RJ, Barnes E, Rogers TR. Is it time to stop using chloramphenicol on the eye? Fears are based on only six cases. BMJ 1995; 311: 450.
28. Cox J, Roderick EM. General practitioners would expect to see aplasia roughly once each century. BMJ 1995; 311: 451.
29. Gordon-Smith EC, Marsh JCW, Geary CG. Prospective study of aplastic anaemia should give definitive answer. BMJ 1995; 31: 450.
30. News in Brief. BMJ 2005; 330: 1406.
31. Frauenfelder FW, Frauenfelder FT. Perspective. Scientific challenges in post-marketing surveillance of ocular adverse drug reactions. Am J Ophthalmol 2007; 143: 145-9.
32. Walker S, Diaper CJM. Bowman R et al. Lack of evidence for systemic toxicity following chloramphenicol use. Eye 1998; 12: 875-9.
33. Trope GE, Lawrence JR, Hind VMD et al. Systemic absorption of topically applied chloramphenicol eye drops. Br J Ophthalmol 1979; 63: 690-1.
34. Besamusca FW, Bastaensen LA. Blood dyscrasias and topically applied chloramphenicol in ophthalmology. Doc Ophthalmol 1986; 64: 87-95.
35. Abrams SM, Degnan TJ, Vinciguerra V. Marrow aplasia following topical application of chloramphenicaol eye ointment. Arch Int Med 1980; 140: 576.
36. Brodsky E, Biger Y, Zeiden Z et al. Topical application of chloramphenicol eye ointment followed by fatal bone marrow aplasia. Isr J Med 1989; 25: 54.